Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 9/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910188 | 0.92 | CNR1 (0.49) | CNR1CNR2PPARAKDM4EMEN1 | |
| SCHEMBL4612318 | 0.90 | CNR1 (0.58) | CNR1CNR2PPARA | |
| SCHEMBL4910943 | 0.90 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL4907958 | 0.90 | CNR1 (0.48) | CNR1CNR2GABRA2GABRB2PPARA | |
| SCHEMBL4914356 | 0.88 | GABRA2 (0.60) | CNR1CNR2GABRA2GABRB2PPARA | |
| SCHEMBL4193262 | 0.88 | CNR1 (0.60) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4913629 | 0.87 | CNR1 (0.49) | CNR1CNR2PPARAKDM4EMEN1 | |
| SCHEMBL12053889 | 0.85 | CNR1 (0.62) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL13814761 | 0.84 | CNR2 (0.63) | CNR1CNR2PPARA | |
| SCHEMBL4611745 | 0.82 | CNR2 (0.58) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR1 597/4885CNR2 480/4885GABRA2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.